艾迪藥業(688488.SH)擬對龍澤製藥投資5000萬元 將獲得其增資後4.76%股權
格隆匯1月7日丨艾迪藥業(688488.SH)公佈,為進一步完善公司(“投資方”)在抗病毒領域的產業發展佈局,提升公司未來在該領域的競爭力,公司擬與石家莊龍澤製藥股份有限公司(“龍澤製藥”、“標的公司”)簽署投資協議。根據各方擬簽署的投資協議,公司擬以現金方式對龍澤製藥投資人民幣5000萬元,以人民幣10億元的投前估值認購龍澤製藥新增註冊資本人民幣400萬元,相較於未經審計的賬面淨資產的溢價率為397.67%。此次交易完成後,龍澤製藥的註冊資本自人民幣8000萬元增加至人民幣8400萬元,公司將獲得龍澤製藥增資後4.76%的股權。
此次對外投資事項是基於公司戰略發展做出的審慎決策。公司在做好抗病毒領域創新產品的研發並推進產品上市的同時,積極開展上游原料藥供應商的合作部署。公司此次投資龍澤製藥後將成為龍澤製藥的股東,將來,公司抗艾滋病單片複方製劑ACC008片獲得批准上市後,龍澤製藥亦將成為公司重要的原料藥供應商。此次投資將有助於進一步強化雙方的深度戰略合作關係,發揮各自在抗病毒領域的領先優勢,有利於穩定公司原料藥供應渠道,為公司發展帶來積極影響,符合公司未來發展戰略。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.